|
Secondary Biliary Cholangitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
|
18422935 |
2008 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis.
|
18507500 |
2008 |
|
Biliary Cirrhosis, Primary, 1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
|
18422935 |
2008 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis.
|
18507500 |
2008 |
|
No-Reflow Phenomenon
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion.
|
16824628 |
2007 |
|
Slow-Flow Phenomenon
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion.
|
16824628 |
2007 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We report that fibrin-mediated angiogenesis was inhibited and tumor growth delayed following postnatal deletion of Tgfbr2 in the endothelium of Cdh5-CreERT2 Tgfbr2fl/fl mice (Tgfbr2iECKO mice).
|
30855280 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We observed a decrease of tumor myeloid cell Shb mRNA in the tamoxifen treated Cdh5-CreERT2/Shb<sup>flox/flox</sup> mice, which was not present when the mice had undergone a preceding bone marrow transplantation using wild type bone marrow.
|
31101877 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, VE-cadherin expression had no effect on tumor cell proliferation in monocultures while co-culturing with endothelial cells enhanced tumor cell proliferation due to integration of the tumor cells into monolayer where they form VE-cadherin-mediated cell contacts with the endothelium.
|
29143117 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RF-assisted gadofullerene nanoparticles induces rapid tumor vascular disruption by down-expression of tumor vascular endothelial cadherin.
|
29459323 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.
|
28655790 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intermedin: a novel regulator for vascular remodeling and tumor vessel normalization by regulating vascular endothelial-cadherin and extracellular signal-regulated kinase.
|
22922959 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Extensive in vitro and in vivo lineage analyses, including single cell clonal studies, further show that a subpopulation of the CD133(+) stem-like cell fraction is multipotent and capable of differentiation along tumour and endothelial lineages, possibly via an intermediate CD133(+)/CD144(+) progenitor cell.
|
21102433 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
VE-cadherin/CDH5 plays a role in tumor-associated angiogenesis.
|
20457567 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Accordingly, VE-cadherin gene inactivation by antisense morpholino oligonucleotide injection inhibits tumor neovascularization without affecting the development of intersegmental and subintestinal vessels.
|
17409396 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, inactivation of Cdh1 and Cdh5 is likely to cooperate with the loss of p53, suggesting a possible tumor suppressive function of these genes in mammary carcinogenesis.
|
17327688 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Frozen sections from breast cancer primary tumours (tumour n = 114, background n = 30) were immunostained with VE-cadherin, factor VIII and PECAM-1 antibodies and microvessel number was assessed.
|
15810954 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis.
|
15735710 |
2005 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
These results demonstrated that serum activates EphA2 and up-regulates twist/VE-cadherin, which in turn activate AKT that up-regulates MMP-2 and LAMC2, thereby inducing the invasion and VM of human PCa PC-3 cells.
|
30797819 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Whole-Transcriptome Analysis of CD133+CD144+ Cancer Stem Cells Derived from Human Laryngeal Squamous Cell Carcinoma Cells.
|
29949786 |
2018 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
HOXA-AS2 knockdown attenuated cell viability, migration, invasion, and VM formation in glioma cells and inhibited the expression of vascular endothelial-cadherin (VE-cadherin), as well as the expression and activity of matrix metalloproteinase matrix metalloproteinase (MMP)-2 and MMP-9. miR-373 was downregulated in glioma samples and cell lines and suppressed malignancy in glioblastoma cells.
|
29310118 |
2018 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Although expressed in tumour cells of various malignancies, cadherin 5 (CDH5), also known as vascular endothelial cadherin, plays an important role in homotypic cell-cell adhesion among epithelial cells.
|
27466381 |
2017 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Cadherin 5 (CDH5) is important for adhesion in epithelial cells, and expressed in tumor cells in several malignancies.
|
29187459 |
2017 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
High CDH5 expression was significantly associated with the following clinicopathological variables related to tumour progression: depth of invasion (p=0.012), venous invasion (p=0.013), lymphatic invasion (p=0.001), metastatic lymph nodes (p=0.009), pathological stage (p=0.008) and distant metastasis or recurrent disease (p=0.009).
|
27466381 |
2017 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion.
|
27010749 |
2016 |